Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



3 Reasons the Market Is Down on Gilead Sciences

After a solid two-year run, Gilead Sciences  (NASDAQ: GILD  ) has fallen from investors graces, down for the year. The biotech has become increasingly reliant on its hepatitis C drug Sovaldi, with competition from AbbVie (NYSE: ABBV  ) and Merck (NYSE: MRK  )  around the corner.

In the slideshow below, you'll find three reasons investors are down on Gilead Sciences and thoughts on the biotech's future.

More companies poised for incredible growth
You can uncover David Gardner's scientific approach to crushing the market and his carefully chosen six picks for ultimate growth in a premium report available for free today. Click here now for access.

Read/Post Comments (4) | Recommend This Article (9)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On April 18, 2014, at 7:50 PM, ralph0865 wrote:

    This article simply is of no use. Zero meaning!

  • Report this Comment On April 19, 2014, at 4:27 PM, badeconomy wrote:

    Gilead is # one drug maker in the world and all the noise make gild more valuable than ever before.

  • Report this Comment On April 19, 2014, at 9:18 PM, Nala wrote:

    This article is the poorest and most biased compilation of garbage I've seen in a long time.

    Institutions, accredited investors and most all of the analysts rate GILD a buy.

    Reading this article convinced me of one thing and one thing only: to never waste another minute on anything publish by this author.

  • Report this Comment On April 21, 2014, at 1:09 AM, Daedalus43 wrote:

    MF should have some way of including the author on the link so we don't click on it. Smelli Orelli has no place in anyone's DD.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2919910, ~/Articles/ArticleHandler.aspx, 8/27/2015 10:37:50 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Brian Orelli

Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.

Today's Market

updated 1 hour ago Sponsored by:
DOW 16,654.77 369.26 2.27%
S&P 500 1,987.66 47.15 2.43%
NASD 4,812.71 115.17 2.45%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/27/2015 4:00 PM
GILD $107.99 Up +1.03 +0.96%
Gilead Sciences CAPS Rating: *****
ABBV $64.51 Up +1.37 +2.17%
AbbVie Inc. CAPS Rating: ****
MRK $54.95 Up +0.53 +0.97%
Merck & Co., Inc. CAPS Rating: ****